The area under the ROC curve (AUC) for predicting 3-year DFS was 0.907 and 0.908 in the training and validation sets, respectively.<h4>Conclusion</h4>Our findings reveal that an immune-poor tumour microenvironment and HER2-low biology are key, complementary determinants of intrinsic resistance to standard chemotherapy in premenopausal TNBC. This evidence concerns the gene ERBB2 and neoplasm.